Motif Bio PLC wants to raise £19.4m ($25m) through issuing new ordinary shares. It will use the money to complete its second Phase III study for iclaprim, its novel antibiotic for acute bacterial skin and skin structure infections (ABSSI) and to file for an NDA and marketing authorization.
Motif Bio Seeks Cash For Novel Antibiotic
Motif Bio wants to raise £19.4m to further develop iclaprim, its novel antibiotic candidate for acute bacterial skin and skin structure infections.
